Karel Allegaert is a paediatrician (1999), neonatologist (2000) and clinical pharmacologist (2003), and is currently appointed at KU Leuven, departments of Development and Regeneration, and Pharmaceutical and Pharmacological Sciences as full professor, with an additional appointment as senior consultant (10%) at Erasmus MC, Rotterdam (Hospital Pharmacy). His research has its focus perinatal and pediatric clinical pharmacology and its co-variates (maturational, non-maturational, pharmacogenetics, disease-related). In a truly international and interdisciplinary connection and collaboration, this resulted in a rather extended scientific output (650 PubMed papers, H index 55, https://www.webofscience.com/wos/author/record/C-3611-2016), and about 50 textbook chapters. The most relevant science categories are pediatrics, pharmacology and pharmacy, medicine research, microbiology and microbiology, toxicology, and lactation-related drug exposure. Links to retrieve the scientific output, as accessible in the public domain: https://www.researchgate.net/profile/Karel-Allegaert. The commitment to create societal impact is reflected in advisory tasks within the field of pharmacology and medicine, like membership of the commission on human medicines; council member Royal Academy of Medicine Belgium (since 2015); member trial board, KCE Belgium. He is also member of the HCP-WP and member of the expert screening panel on medical devices, of the European Medicines Agency, and highly involved in different pediatric formularies (kinderformularium, Australasian neonatal formulary, MADAM).